India's pharmaceutical supply chain remains 65% dependent on Chinese imports for APIs and KSMs.
NITI Aayog identifies weak innovation and high R&D costs as major sector challenges.
The government is urging companies to move toward high-value segments to improve market positioning.
India currently supplies a significant portion of generic medicine demand to the US, UK, and Africa.